Dutch company BAC (Bio Affinity Company) has entered into a collaboration agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group.
BAC's CaptureSelect customised affinity ligands have been selected by sanofi pasteur as they potentially offer high stability and specificity for process-scale purification of some of its vaccine products.
Manufactured using a high-yielding proprietary animal-free, yeast-based expression system, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity media.
'This is a significant collaboration for BAC,' said Dr Laurens Sierkstra, ceo of BAC. 'This latest agreement further endorses the suitability of our CaptureSelect technology for commercial-scale bioprocessing.'